Superior bioavailability of EPA and DHA from a L-lysine salt formulation: a randomized, three-way crossover study

Christiane Schön; Antje Micka; Vishnupriya  Gourineni; Roberta Bosi

doi:10.29219/fnr.v68.11028

Christiane Schön BioTeSys GmbH
Antje Micka BioTeSys GmbH
Vishnupriya Gourineni Evonik Corporation
Roberta Bosi Evonik Operations GmbH

DOI: https://doi.org/10.29219/fnr.v68.11028

Keywords: omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, bioavailability, pharmacokinetic, lysine, ethyl ester, triglyceride

Abstract

Background: Omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are polyunsaturated fatty acids (PUFAs) with notable health benefits. Due to limited physiological production and insufficient dietary supply, external supplementation is important.

Objective: This study aimed to compare the pharmacokinetics and bioavailability of EPA and DHA in AvailOm^® omega-3-lysine salt (Lys-FFA) versus standard ethyl ester (EE) and triglyceride (TG) formulations after a single oral dose in healthy subjects.

Design: A randomized, three-way crossover study was conducted with 21 healthy subjects.

Results: Twenty-one subjects (10 men, 11 women) completed the study. The average age was 41.7 years, and the mean body mass index was 23.0 kg/m². The Lys-FFA formulation showed significantly higher uptake of omega-3 fatty acids (EPA+DHA combined and each individually) compared to EE. Specifically, Lys-FFA had a 9.33-fold (0–12 h) and 8.09-fold (0–24 h) higher bioavailability of EPA+DHA than EE and a 1.57-fold (0–12 h) and 1.44-fold (0–24 h) higher bioavailability than TG. ΔCmax and Tmax also favored Lys-FFA over EE.

Discussion: Under fasting conditions, the absorption of EPA and DHA from EE is limited due to the need for enzymatic cleavage before absorption. This requirement is bypassed with Lys-FFA, which does not need cleavage.

Conclusions: The study demonstrates that EPA and DHA lysine salt (Lys-FFA) offers superior bioavailability compared to EE and triglyceride forms, presenting a more effective supplementation option.

German Clinical Trials Register, DRKS-ID: DRKS00029183

Downloads

Download data is not yet available.

References

tr>
1.
Cholewski M, Tomczykowa M, Tomczyk M. A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids. Nutrients 2018; 10(11): 1662. doi: 10.3390/nu10111662

2.
Lange KW. Omega-3 fatty acids and mental health. Glob Health J 2020; 4(1): 18–30. doi: 10.1016/j.glohj.2020.01.004

3.
Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr 2012; 3(1): 1–7. doi: 10.3945/an.111.000893

4.
Innes JK, Calder PC. Marine omega-3 (N-3) fatty acids for cardiovascular health: an update for 2020. Int J Mol Sci 2020; 21(4): 1362. doi: 10.3390/ijms21041362

5.
Dicklin MR, Anthony JC, Winters BL, Maki KC. ω-3 polyunsaturated fatty acid status testing in humans: a narrative review of commercially available options. J Nutr 2024; 154(5): 1487–504. doi: 10.1016/j.tjnut.2024.03.015

6.
Maki KC, Palacios OM, Buggia MA, Trivedi R, Dicklin MR, Maki CE. Effects of a self-micro-emulsifying delivery system formulation versus a standard ω-3 acid ethyl ester product on the bioavailability of eicosapentaenoic acid and docosahexaenoic acid: a study in healthy men and women in a fasted state. Clin Ther 2018; 40(12): 2065–76. doi: 10.1016/j.clinthera.2018.10.014

7.
Fuentes NR, Kim E, Fan Y-Y, Chapkin RS. Omega-3 fatty acids, membrane remodeling and cancer prevention. Mol Aspects Med 2018; 64: 79–91. doi: 10.1016/j.mam.2018.04.001

8.
Abedi E, Sahari MA. Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. Food Sci Nutr 2014; 2(5): 443–63. doi: 10.1002/fsn3.121

9.
Lane K, Derbyshire E, Li W, Brennan C. Bioavailability and potential uses of vegetarian sources of omega-3 fatty acids: a review of the literature. Crit Rev Food Sci Nutr 2014; 54(5): 572–9. doi: 10.1080/10408398.2011.596292

10.
Manusama K, Balvers M, Diepeveen-de Bruin M, Headley L, Bosi R, Schwarm M, et al. In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA. Prostaglandins Leukot Essent Fatty Acids 2021; 164: 102232. doi: 10.1016/j.plefa.2020.102232

11.
Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2013; 89(1): 1–8. doi: 10.1016/j.plefa.2013.03.010

12.
Calder PC. Very long-chain n-3 fatty acids and human health: fact, fiction and the future. Proc Nutr Soc 2018; 77(1): 52–72. doi: 10.1017/S0029665117003950

13.
Ian Givens D, Gibbs RA. Current intakes of EPA and DHA in European populations and the potential of animal-derived foods to increase them. Proc Nutr Soc 2008; 67(3): 273–80. doi: 10.1017/S0029665108007167

14.
Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag 2013; 9: 563–73. doi: 10.2147/VHRM.S50464

15.
Lowe ME. The triglyceride lipases of the pancreas. J Lipid Res 2002; 43(12): 2007–16. doi: 10.1194/jlr.r200012-jlr200

16.
Lohner S, Fekete K, Marosvölgyi T, Decsi T. Gender differences in the long-chain polyunsaturated fatty acid status: systematic review of 51 publications. Ann Nutr Metab 2013; 62(2): 98–112. doi: 10.1159/000345599